Chromadex Corp. Hits New 52-Week Low at USD 3.50

Chromadex Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 3.50 on June 2, 2026. This significant decline highlights the company's struggles in a competitive market, particularly as it has underperformed relative to the S&P 500, which has seen a return of 28.2% over the same period. Despite a notable increase in profits by 335.6%, Chromadex's stock has experienced a staggering decline of 66.64% in the past year. The company's financial metrics reveal a P/E ratio of 19.00 and a Price to Book ratio of 5.44, indicating a fair valuation in the context of its market position. However, the return on equity stands at 28.91%, suggesting a mixed picture of profitability. Additionally, Chromadex's operating cash flow has been reported at USD 4.36 million, with a debt-equity ratio of -0.90, reflecting a complex financial landscape. The company also boasts a high institutional ownership of 51.28%, which may provide some stability amid the current volatility. Overall, the recent price movement underscores the challenges Chromadex faces in regaining market traction.